Anti-Inflammatories: Small Molecule Approaches - CHI's Inaugural

The inaugural Anti-Inflammatories: Small Molecule Approaches event, held in San Diego as part of CHIs Fifth Annual Drug Discovery Chemistry convention, included topics covering new therapeutic developments in the field of anti-inflammatory research. This conference report highlights selected presentations on the JAK family of kinases, Btk inhibitors, thyroid hormone analogs, CRAC channel targets, histamine H4 receptor antagonists, and immunoproteasome-LMP7 selective inhibitors. Investigational drugs discussed include tasocitinib (Pfizer Inc), ruxolitinib (Incyte Corp/Novartis AG), INCB-28050 (Incyte Corp/Eli Lilly & Co), AVL-292 (Avila Therapeutics Inc), PCI-32765 (Pharmacyclics Inc), the naproxen analog ATB-346 (Antibe Therapeutics Inc), JNJ-28307474 (Johnson & Johnson Pharmaceutical Research & Development LLC/Abbott Laboratories), ONX-0914 (Onyx Pharmaceuticals Inc) and CPSI-2364 (Cytokine PharmaSciences Inc).